Key result
The use of internal validation to select a myeloperoxidase cutpoint yielded an estimated integrated discrimination improvement of 10%, which may be overestimated due to overfitting.
No takes yet. Share an insight, caveat, or question.
This editorial highlights the clinical and statistical challenges in establishing valid decision limits for new cardiovascular biomarkers, emphasizing the need for robust external validation.
Morrow et al. (2010) conducted an editorial in Stable ischemic heart disease. Myeloperoxidase (MPO) biomarker cutpoints was evaluated. The use of internal validation to select a myeloperoxidase cutpoint yielded an estimated integrated discrimination improvement of 10%, which may be overestimated due to overfitting.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: